Last reviewed · How we verify
Perhyal rinse
Perhyal rinse is a Topical antiseptic rinse Small molecule drug developed by University of Baghdad. It is currently in Phase 3 development. Also known as: BMG0703.
Disrupts bacterial cell membranes and inhibits anaerobic microorganisms in the oral cavity.
Perhyal rinse is a hydrogen peroxide-based oral rinse that works through oxidative antimicrobial action to disinfect and cleanse oral tissues. Used for Oral antisepsis and wound cleansing, Gingivitis and periodontal disease management.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Perhyal rinse |
|---|---|
| Also known as | BMG0703 |
| Sponsor | University of Baghdad |
| Drug class | Topical antiseptic rinse |
| Target | Bacterial cell membranes and anaerobic microorganisms |
| Modality | Small molecule |
| Therapeutic area | Dentistry / Oral Health |
| Phase | Phase 3 |
Mechanism of action
Perhyal rinse acts as a topical antiseptic that disrupts the integrity of bacterial cell membranes, leading to bacterial cell death. It specifically targets anaerobic microorganisms commonly found in the oral cavity that contribute to periodontal disease and oral infections.
Approved indications
Common side effects
- Tooth bleaching or discoloration
- Oral irritation or sensitivity
- Temporary gum tenderness
Key clinical trials
- Mouthwashes for Gingivitis: Comparing a Hydrogen Peroxide-Hyaluronic Acid Mix, Hyaluronic Acid, and Chlorhexidine, A Triple-Blind Clinical Trial (NA)
- Anti-inflammatory and Anti-plaque Efficacies of Mouth Rinse Containing Hyaluronic Acid and Hydrogen Peroxide (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Perhyal rinse CI brief — competitive landscape report
- Perhyal rinse updates RSS · CI watch RSS
- University of Baghdad portfolio CI
Frequently asked questions about Perhyal rinse
What is Perhyal rinse?
How does Perhyal rinse work?
Who makes Perhyal rinse?
Is Perhyal rinse also known as anything else?
What drug class is Perhyal rinse in?
What development phase is Perhyal rinse in?
What are the side effects of Perhyal rinse?
What does Perhyal rinse target?
Related
- Drug class: All Topical antiseptic rinse drugs
- Target: All drugs targeting Bacterial cell membranes and anaerobic microorganisms
- Manufacturer: University of Baghdad — full pipeline
- Therapeutic area: All drugs in Dentistry / Oral Health
- Also known as: BMG0703
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing